Business Wire

NY-CLARITY-AI

17.3.2022 18:06:12 CET | Business Wire | Press release

Share
Clarity AI: Only 7% of a Sample of 31,000 Equity Funds Have More Than 10% “Green Revenues,” as Defined in the EU Taxonomy

The EU Taxonomy aims to align all market stakeholders on what is considered sustainable in the context of the EU, but investors need greater transparency on just how green the funds they are buying really are. Analysis by Clarity AI, the market-leading, global sustainability technology platform, reveals significant differences between fund revenues aligned with green – and EU Taxonomy related – objectives across different types of sustainable investment products in the market today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005718/en/

Under the Sustainability Finance Disclosure Regulation (or SFDR), investors need to report the EU Taxonomy alignment as part of the sustainability profile of funds, which need to be classified into one of three categories:

  • Article 6: non-sustainable funds
  • Article 8: funds that promote sustainable characteristics but not as an overarching objective
  • Article 9: funds that have been specifically created to address sustainability goals

In a whitepaper titled “EU Taxonomy: Using Tech to Analyze ‘Green’ Fund Performance,” Clarity AI analyzed an investable universe of 31,000 equity funds on how these products perform against new EU Taxonomy requirements and assessed the common traits across funds, which are often branded in some way as “green.” The analysis shows that:

  • Globally, 3.6% of revenues can be considered green (“green revenues”) – that is, they contribute to mitigating climate change.
  • Only 7% of the 31,000 equity funds analyzed have more than 10% green revenues, as defined in the EU taxonomy.1
  • Article 9 climate-branded funds present four times higher alignment with the EU taxonomy than the overall sample average, with 15% of revenues classified as green. Article 8 funds, however, have a similar alignment to the average, with 3.9% green revenues.
  • Funds focused on sectors that are doing heavy lifting in the green transition, such as utilities, show a higher exposure and alignment, with 25% green revenues.
  • Funds with equity themes, such as alternative energy, are naturally more aligned with a green economy, with up to 27% green revenues.

Patricia Pina, Head of Product Research & Innovation at Clarity AI, said: “Considering the disparate definitions of and frameworks for sustainability all around the world, we can look to the EU Taxonomy as a pioneer in setting a common standard to align a large segment of global market stakeholders. At Clarity AI, we believe regulation needs to be supported by detailed, data-led insights, and transparency cannot be a nice-to-have. It is a must-have.

“The EU recognizes that a key requirement to further the development of the sustainable investment market is ‘access to high-quality sustainability-related data.’ 2 This high-quality data also means moving away from subjectivity and using an objective and fact-based definition of what should be considered ‘green,’ ‘social,’ ‘environmental,’ and so on. The EU taxonomy gives us a common language that will enable stronger decision making and an acceleration to a more sustainable economy.

“Reliable, transparent insights are at the heart of fact-based sustainable finance. They should become the norm in making informed decisions around ‘green’ investing.”

Notes to editors

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors and organizations. As of December 2021, Clarity AI’s platform analyzes more than 30,000 companies, 180,000 funds, 198 countries and 187 local governments, and delivers data and analytics for investing, corporate research and reporting. Clarity AI has offices in the US, Europe, and the Middle East. Clarity AI’s client network manages trillions in assets under management. clarity.ai

Methodology

Clarity AI developed a comprehensive assessment of how companies and funds align with the EU Taxonomy classification of sustainability using its proprietary sustainable analytics technology platform. Clarity AI draws on the broadest possible spectrum of tools and data sources available to increase the coverage, precision and objectivity of the sustainability analysis, while remaining transparent. The method in this paper relies on the three steps of Clarity AI's EU Taxonomy analysis and displays two key metrics that investors will need to report:

  • % Eligible green revenue: as defined by revenues exposed to the activities outlined in the EU Taxonomy
  • % Aligned green revenue: which builds upon eligible activities and embeds an assessment of the technical screening criteria, DNSH and SS requirements

Through its sustainability tech platform, Clarity AI can scalably assess >180,000 funds and >30,000 organizations. For this report, Clarity AI selected a subset of its universe where it takes a deeper look into the EU Taxonomy alignment for more than 31,000 funds globally. Clarity AI focused the analysis on the parent funds (independent of the asset classes) of equity-only funds for which it has enough characterization of the fund (e.g., assets under management, description, etc.). For the sake of comparison, they cover a broad range of regions, sectors and strategies.

1 As per the EU Taxonomy’s methodology of calculating alignment: Use the weighted average of the percent green revenues by company, which is based on the weights within a portfolio

2 As per the European Commission study published in June 2021

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye